You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
微創腦科學(02172.HK)2022年經調整淨溢利1.31億元 同比增長38.9%
格隆匯 03-29 22:03

格隆匯3月29日丨微創腦科學(02172.HK)公吿,於2022財年,集團實現收入人民幣5.47億元,較上年增長43.0%,其中,國際(非中國)業務收入為人民幣2190萬元,較上年增長3,492%。2022年度經調整淨溢利為人民幣1.31億元,較上年增長38.9%。公司董事會於截至2022年12月31日止年度內並無建議派付任何股息。

2022年度,面對市場環境及疫情的挑戰,集團積極採取一切措施保障生產經營,堅持銷售渠道下沉戰略,提升線上、線下醫學教育培訓力度,同時加快全球業務佈局,實現收入持續高速增長。

集團已建立一支具有專業醫療背景且經驗豐富的治療方案推廣團隊,持續向市場輸出創新神經介入治療理念,為患者和醫生提供腦血管疾病一體化解決方案,包括術式和產品宣教、治療方案建議、手術及器械使用培訓、臨牀支持及術後跟蹤隨訪等,持續提升醫院滲透率,夯實國產品牌領先地位。截至2022年末,公司的治療方案推廣團隊擁有近百名員工,平均行業經驗超過8年。此外,本集團已與超過200家經銷商及二級經銷商建立合作關係,銷售渠道覆蓋全國31個省份、直轄市及自治區。

截至2022年末,公司的產品累計在全國約2,600家醫院獲得臨牀應用,涵蓋超過1,400家三級醫院及所有中國國家卒中中心排名前100的醫院,累計支持約125,000台神經介入手術。2022年,集團產品新開拓約500家醫院,其中縣級醫院佔250家以上,逐步鞏固基層市場。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account